GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » Gross Margin %

CytoDyn (CytoDyn) Gross Margin % : 0.00% (As of Feb. 2024)


View and export this data going back to 2005. Start your Free Trial

What is CytoDyn Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. CytoDyn's Gross Profit for the three months ended in Feb. 2024 was $0.00 Mil. CytoDyn's Revenue for the three months ended in Feb. 2024 was $0.00 Mil. Therefore, CytoDyn's Gross Margin % for the quarter that ended in Feb. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for CytoDyn's Gross Margin % or its related term are showing as below:


During the past 13 years, the highest Gross Margin % of CytoDyn was -27547.74%. The lowest was -27547.74%. And the median was -27547.74%.

CYDY's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.45
* Ranked among companies with meaningful Gross Margin % only.

CytoDyn had a gross margin of N/A% for the quarter that ended in Feb. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for CytoDyn was 0.00% per year.


CytoDyn Gross Margin % Historical Data

The historical data trend for CytoDyn's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Gross Margin % Chart

CytoDyn Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -27,547.74 -

CytoDyn Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CytoDyn's Gross Margin %

For the Biotechnology subindustry, CytoDyn's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoDyn's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Gross Margin % distribution charts can be found below:

* The bar in red indicates where CytoDyn's Gross Margin % falls into.



CytoDyn Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

CytoDyn's Gross Margin for the fiscal year that ended in May. 2023 is calculated as

Gross Margin % (A: May. 2023 )=Gross Profit (A: May. 2023 ) / Revenue (A: May. 2023 )
=-20.6 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 20.633) / 0
= %

CytoDyn's Gross Margin for the quarter that ended in Feb. 2024 is calculated as


Gross Margin % (Q: Feb. 2024 )=Gross Profit (Q: Feb. 2024 ) / Revenue (Q: Feb. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


CytoDyn  (OTCPK:CYDY) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

CytoDyn had a gross margin of N/A% for the quarter that ended in Feb. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


CytoDyn Gross Margin % Related Terms

Thank you for viewing the detailed overview of CytoDyn's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoDyn (CytoDyn) Business Description

Traded in Other Exchanges
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Executives
Tyler Blok officer: EVP of Legal Affairs 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes director
Ryan Dunlap director 310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman officer: President 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese officer: Chief Financial Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor officer: Chief Operating Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland officer: CFO, Treasurer and Secretary 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660